Inamed Corporation (NASDAQ:IMDC) announced today that Phase 3 clinical data for the three formulations of Juvederm(TM) (Juvederm(TM) 24HV, Juvederm(TM) 30HV, and Juvederm(TM) 30), a next generation, non-animal, cross linked hyaluronic acid based dermal filler, will be presented at the 64th Annual Meeting of the American Academy of Dermatology in San Francisco, California.
